PrimeC New Data to Be Presented at AD/PD™ 2026 Conference

PrimeC New Data to Be Presented at AD/PDâ"¢ 2026 Conference Accessibility StatementSkip Navigation Dr. Christian Lunetta to Present "From PARADIGM to PARAGON: Advancing PrimeC for ALS through Phase 2 Clinical and Biomarker Insights toward a Global Phase 3 Trial" CAMBRIDGE, Mass., March 18, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.(NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announce ...